Revvity, Inc. (RVTY)
Trading disclosure
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.
Learn moreKey Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
|
Dr. Prahlad R. Singh Ph.D.
|
CEO, President & Director | 3.56M | -- | 1965 |
|
Mr. Maxwell Krakowiak
|
Senior VP & CFO | 1.18M | -- | 1990 |
|
Mr. Tajinder S. Vohra
|
Senior Vice President of Global Operations | 1.03M | 195.09k | 1966 |
|
Mr. Joel S. Goldberg
|
Senior VP of Administration, General Counsel & Secretary | 1.25M | 689.38k | 1969 |
|
Ms. Miriame Victor
|
Senior Vice President & Chief Business Officer | 1.04M | -- | 1981 |
|
Ms. Anita Gonzales
|
Chief Accounting Officer, VP & Controller | -- | -- | 1976 |
|
Mr. Bryan A. Kipp
|
Senior VP of Technology & Licensing | -- | -- | -- |
|
Dr. Madhuri Hegde FACMG, Ph.D.
|
Senior VP & Chief Scientific Officer | -- | -- | -- |
|
Mr. Stephen Barr Willoughby
|
Senior VP of Investor Relations & Head of ESG | -- | -- | -- |
|
Ms. Magali Four
|
Senior VP and Chief People & Culture Officer | -- | -- | -- |
Revvity, Inc.
- Sector:
- Healthcare
- Industry: Diagnostics & Research
- Full Time Employees:
- 11,000
Description
Revvity, Inc. provides health sciences solutions, technologies, and services. The company offers instruments, reagents, software, subscriptions, detection and imaging technologies, extended warranties, and training and services; and instruments, reagents, and assay platforms and software products for early detection of common and rare conditions, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. It also develops technologies that enable and support genomic workflows using protein coupled receptors and next-generation DNA sequencing for oncology, immunodiagnostics, and drug discovery. It serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies under the AutoDELFIA, chemagic, Chitas, CNGnome, DELFIA, DELFIA Xpress, EONIS, EUROArray, EUROIMMUN, EUROLabWorkstation, EUROLINE, EUROPattern, Evolution Evoya, GSP, Haoyuan, IDS Immunodiagnosticsystems, IDS-i10, IDS-i10T, IDS-i20, IDS-iSYS, iLab, iQ, LifeCycle, LimsLink, Migele, NeoBase, NeoLSD, NEXTFLEX, Panthera Puncher, PreNAT II, Prime, RONIA, SimplicityChrom, Specimen Gate, Superflex, Symbio, T-SPOT, Vanadis, ViaCord, VICTOR2, and WholePanel brand names, as well as under the Accell, AlphaLISA, AlphaPlex, AlphaScreen, Alpha SureFire, AssayMate, BIOCHIPs, BioLegend, Bioo Scientific, BioQule, Brilliant Violet, Ce3D, CellCarrier, Cellaca, Celigo, Cellometer, cell::explorer, Cell-Vive, Chalice, ChemDraw, CHOSOURCE, Dharmacon, and DharmaFECT brand names. The company was formerly known as PerkinElmer, Inc. and changed its name to Revvity, Inc. in April 2023. Revvity, Inc. was founded in 1937 and is headquartered in Waltham, Massachusetts.
Corporate Governance
Upcoming Events
November 3, 2026 at 12:30 PM UTC
Revvity, Inc. Earnings Date
November 13, 2026 at 12:00 AM UTC
Dividend Date
Recent Events
October 23, 2026 at 12:00 AM UTC
Ex-Dividend Date
June 1, 2026 at 12:00 AM UTC
SD: Specialized Disclosure Report filed pursuant to Section 1502 of the Dodd-Frank Wall Street Reform and Consumer Protection Act relating to the use of conflict minerals (Rule 13p-1)
